This site is intended for health professionals only

Home / Clinical / Pregabalin and gabapentin reclassified as class C drugs, Government announces

Pregabalin and gabapentin reclassified as class C drugs, Government announces

By Léa Legraien

16 Oct 2018

Pregabalin and gabapentin will be reclassified as class C drugs next year following a rising numbers of deaths linked to the drugs, the Government has said.

The Home Office announced yesterday (15 October) that the prescription-only anti-convulsant medicines will be reclassified from April 2019.

Under the changes, pregabalin and gabapentin will face tighter controls to help prevent people from stockpiling, misusing and becoming addicted to the drugs, minister for crime, safeguarding and vulnerability Victoria Atkins said.

This means that it will be illegal for people to possess the drugs without a prescription, which will have to be ‘physically’ signed by the GP before being accepted in a pharmacy. Pharmacists will also be required to dispense the drugs within 28 days of the prescription being issued.


‘Serious side effects’

The drugs can cause elevated mood, but can have ‘serious side effects, particularly when used in combination with other drugs’, the Home Office said.

This follows a consultation launched last year, which looked at whether the two medicines should be controlled as class C drugs under the Misuse of Drugs Act 1971 and defined as schedule 3 drugs as part of the Misuse of Drugs Regulations 2001.


Stronger controls in place


Ms Atkins said: ‘While drug misuse is lower now than it was 10 years ago, we remain committed to reducing it and the harm it causes.

‘That is why we have published a comprehensive strategy to tackle the illicit drug trade, protect the most vulnerable and help those with drug dependency to recover and turn their lives around.’

According to the Home Office, pregabalin and gabapentin are ‘often used by people who misuse opioids’, highly resulting in criminal behaviour to try and get hold of the drugs


Supporting pharmacists in managing stock


Although Royal Pharmaceutical President (RPS) Ash Soni welcomed the move, he argued that pharmacies will need support to ensure they do not end up with out-of-date stocks of the drugs.

He told The Pharmacist today (16 October): ‘These [drugs] are widely prescribed and have a wide range of strengths.

‘It is likely that there will be some reduction in the prescribing of these drugs and pharmacies will need support in managing their stock holding to ensure they meet patient demand but not end up with significant stocks that go out of date.

‘It will be important that patients are made aware of the changes, to ensure that they understand the new requirements for prescriptions, particularly regarding the time limits for dispensing and restrictions in prescribed quantity.’

Want news like this straight to your inbox?

Latest News

Covid vaccine
Pharmacists to ‘support’ rollout of school Covid vaccinations
A school-based Covid vaccination programme is to start next week, offering children aged 12-15 years...
Consultation with patient
Primary care diabetes drug bill rises 62% in five years
Prescribing for diabetes in primary care now accounts for 12.5% of the total spend on...
flu and covid
Flu jab deliveries from major provider delayed for up to 2 weeks
Some pharmacies in England and Wales could see delays of up to two weeks on deliveries of flu vaccines because...